{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T05:50:28Z","timestamp":1649051428223},"reference-count":30,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Thoracic and Cardiovascular Surgery"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.jtcvs.2015.01.065","type":"journal-article","created":{"date-parts":[[2015,2,12]],"date-time":"2015-02-12T01:47:00Z","timestamp":1423705620000},"page":"1539-1547.e1","source":"Crossref","is-referenced-by-count":5,"title":["Importance of excision repair cross-complementation group 1 and ribonucleotide reductase M1 as prognostic biomarkers in malignant pleural mesothelioma treated with platinum-based induction chemotherapy followed by surgery"],"prefix":"10.1016","volume":"149","author":[{"given":"Lukas","family":"Frischknecht","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayura","family":"Meerang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Soltermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rolf","family":"Stahel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holger","family":"Moch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Burkhardt","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter","family":"Weder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Opitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtcvs.2015.01.065_bib1","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1097\/JTO.0b013e31826915f1","article-title":"Initial analysis of the international association for the study of lung cancer mesothelioma database","volume":"7","author":"Rusch","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtcvs.2015.01.065_bib2","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.jtcvs.2013.01.039","article-title":"The role of surgical cytoreduction in the treatment of malignant pleural mesothelioma: meeting summary of the International Mesothelioma Interest Group Congress, September 11-14, 2012, Boston, Mass","volume":"145","author":"Rusch","year":"2013","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jtcvs.2015.01.065_bib3","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1093\/annonc\/mdm093","article-title":"Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma","volume":"18","author":"Weder","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtcvs.2015.01.065_bib4","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1093\/annonc\/mdq471","article-title":"Mesothelioma","volume":"21","author":"Weder","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtcvs.2015.01.065_bib5","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s11864-011-0154-4","article-title":"Surgical treatment of malignant pleural mesothelioma","volume":"12","author":"Kaufman","year":"2011","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.jtcvs.2015.01.065_bib6","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1200\/JCO.2012.43.0900","article-title":"ERCC1 and RRM1: ready for prime time?","volume":"31","author":"Besse","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtcvs.2015.01.065_bib7","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1378\/chest.127.3.978","article-title":"ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer","volume":"127","author":"Simon","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.jtcvs.2015.01.065_bib8","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1056\/NEJMoa060570","article-title":"DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy","volume":"355","author":"Olaussen","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtcvs.2015.01.065_bib9","doi-asserted-by":"crossref","first-page":"6497","DOI":"10.1158\/0008-5472.CAN-05-4462","article-title":"Suppression of lung tumor formation by the regulatory subunit of ribonucleotide reductase","volume":"66","author":"Gautam","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtcvs.2015.01.065_bib10","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.cllc.2012.09.003","article-title":"Excision repair cross complementation group 1 and thymidylate synthase expression in patients with mesothelioma","volume":"14","author":"Kao","year":"2013","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtcvs.2015.01.065_bib11","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/JTO.0b013e318233d6a9","article-title":"Low ERCC1 expression in malignant pleural mesotheliomas treated with cisplatin and vinorelbine predicts prolonged progression-free survival","volume":"7","author":"Zimling","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtcvs.2015.01.065_bib12","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1158\/1078-0432.CCR-10-2873","article-title":"Thymidylate synthase and excision repair\u00a0cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed\/carboplatin","volume":"17","author":"Zucali","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtcvs.2015.01.065_bib13","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1200\/JCO.2008.17.5604","article-title":"Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma","volume":"27","author":"de Perrot","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtcvs.2015.01.065_bib14","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/nm0798-844","article-title":"Tissue microarrays for\u00a0high-throughput molecular profiling of tumor specimens","volume":"4","author":"Kononen","year":"1998","journal-title":"Nat Med"},{"key":"10.1016\/j.jtcvs.2015.01.065_bib15","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdh059","article-title":"Modified RECIST criteria for assessment of response in malignant pleural mesothelioma","volume":"15","author":"Byrne","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtcvs.2015.01.065_bib16","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/JTO.0000000000000055","article-title":"PI3K\/mTOR signaling in mesothelioma patients treated with induction chemotherapy followed by extrapleural pneumonectomy","volume":"9","author":"Bitanihirwe","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtcvs.2015.01.065_bib17","doi-asserted-by":"crossref","first-page":"e92320","DOI":"10.1371\/journal.pone.0092320","article-title":"Response to first-line chemotherapy in patients with non-small cell lung cancer according to RRM1 expression","volume":"9","author":"Dong","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jtcvs.2015.01.065_bib18","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1038\/sj.onc.1206419","article-title":"Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer","volume":"22","author":"Rosell","year":"2003","journal-title":"Oncogene"},{"issue":"12 Pt 2","key":"10.1016\/j.jtcvs.2015.01.065_bib19","doi-asserted-by":"crossref","first-page":"4215s","DOI":"10.1158\/1078-0432.CCR-040006","article-title":"Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery","volume":"10","author":"Rosell","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtcvs.2015.01.065_bib20","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S1470-2045(10)70244-8","article-title":"The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer","volume":"12","author":"Jordheim","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtcvs.2015.01.065_bib21","doi-asserted-by":"crossref","first-page":"4731","DOI":"10.1200\/JCO.2006.06.1101","article-title":"RRM1 modulated in\u00a0vitro and in\u00a0vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer","volume":"24","author":"Bepler","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtcvs.2015.01.065_bib22","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ajpath.2010.11.029","article-title":"ERCC1 and RRM1 in the international adjuvant lung trial by automated quantitative in situ analysis","volume":"178","author":"Bepler","year":"2011","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jtcvs.2015.01.065_bib23","first-page":"980","article-title":"Wild-type p53 regulates human ribonucleotide reductase by protein-protein interaction with p53R2 as well as hRRM2 subunits","volume":"63","author":"Xue","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtcvs.2015.01.065_bib24","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/his.12264","article-title":"Differences in RRM1 protein expression between diagnostic biopsies and resection specimens, and changes during carboplatin and paclitaxel treatment, in non-small-cell lung cancer","volume":"64","author":"Jakobsen","year":"2014","journal-title":"Histopathology"},{"key":"10.1016\/j.jtcvs.2015.01.065_bib25","first-page":"5597","article-title":"Chemotherapy followed by surgery on the basis of biomarker examination for patients with advanced non-small cell lung cancer","volume":"33","author":"Yokomise","year":"2013","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jtcvs.2015.01.065_bib26","doi-asserted-by":"crossref","first-page":"9510","DOI":"10.1158\/0008-5472.CAN-05-0989","article-title":"In\u00a0vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant","volume":"65","author":"Bergman","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtcvs.2015.01.065_bib27","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s00280-012-1965-0","article-title":"A biomarker profile for predicting efficacy of cisplatin-vinorelbine therapy in malignant pleural mesothelioma","volume":"70","author":"Zimling","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.jtcvs.2015.01.065_bib28","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.cllc.2013.04.013","article-title":"ERCC1, MLH1, MSH2, MSH6, and betaIII-tubulin: resistance proteins associated with response and outcome to platinum-based chemotherapy in malignant pleural mesothelioma","volume":"14","author":"Ting","year":"2013","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtcvs.2015.01.065_bib29","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1214271","article-title":"ERCC1 isoform expression and DNA repair in non-small-cell lung cancer","volume":"368","author":"Friboulet","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtcvs.2015.01.065_bib30","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/FPC.0b013e32834e3572","article-title":"The influence of gemcitabine pathway polymorphisms on treatment outcome in patients with malignant mesothelioma","volume":"22","author":"Erculj","year":"2012","journal-title":"Pharmacogenet Genomics"}],"container-title":["The Journal of Thoracic and Cardiovascular Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022522315001282?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022522315001282?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T06:09:59Z","timestamp":1617602999000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022522315001282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S0022522315001282"],"URL":"https:\/\/doi.org\/10.1016\/j.jtcvs.2015.01.065","relation":{},"ISSN":["0022-5223"],"issn-type":[{"value":"0022-5223","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]}}}